Ketorolac Tromethamine 30 MG/ML for Obstetric Analgesia (KetoPltAgg Trial)

"Presently, Ketorolac Tromethamine 30 MG/ML is being trialled in 38 separate clinical studies. 8 of those are currently at Phase 3 and the majority take place in Los Angeles, California; yet trials for this medication span a total of 57 locations across the United States."

"Ocular itching may be treated with Ketorolac Tromethamine 30 MG/ML, which can also assist in managing pain, inducing nerve blockage and regulating pupil constriction."

"The safety rating for Ketorolac Tromethamine 30 MG/ML was judged to be 3, as it is a Phase 4 drug and has already been cleared by regulators."

"Recruitment for this trial is currently closed. First posted on January 18th 2021, the study was last updated September 19th 2022. Patients can look into 913 other clinical trials that involve postpartum hemorrhage and 38 studies concerning Ketorolac Tromethamine 30 MG/ML are actively recruiting persons at present."

"This trial has a strict criteria for inclusion, namely postpartum hemorrhage and an age between 18-45. Approximately 40 individuals will be taken into consideration."

"This research is no longer accepting participants, with the initial post having been published on January 18th 2021 and most recent edit occurring on September 19th 2022. If you are looking for alternative trials related to postpartum hemorrhage there are 913 studies presently recruiting patients; 38 of those recruitments involve Ketorolac Tromethamine 30 MG/ML specifically."

"The primary outcome measured in this trial over a 15-minute period following placebo or ketorolac administration is the Platelet Aggregometry Percent Light Transmission. Secondary outcomes include Kinetics (K), Maximum Amplitude (MA), and Reaction time (R) parameters of Thromboelastogram measurements."

"This study necessitates that potential participants are in the 18 to 45 year-old demographic. There is a total of 144 medical studies for younger patients, and 730 clinical trials for those over 65 years old."